search
Back to results

Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis

Primary Purpose

Psychosis

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
PsyGist and Clinician Manual
Sponsored by
New York University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Psychosis

Eligibility Criteria

16 Years - 30 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or females between the ages of 16- 30
  • Current or previous COPE participant
  • Identified as at clinical high risk for psychosis as defined as having at least one of the following: a)attenuated positive symptoms b)brief intermittent positive symptoms

Exclusion Criteria:

  • Meeting CHR via only the Genetic risk and deterioration (GRD) syndrome. If the participant meets the GRD syndrome only, the investigators exclude the rare Genetic risk + deterioration (GRD) syndrome (comprising <1% of CHR cases) because GRD requires having a 1st degree relative with any psychotic disorder, which may be linked with stronger reactions to genetic framings.
  • IQ < 80
  • Inability to adopt hypothetical situation

Sites / Locations

  • New York State Psychiatric Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Clinician Manual

AutoTutor (PsyGist)

Arm Description

Participants in the Clinician Manual arm will be introduced to a trained clinician and will complete one 60-minute session covering equivalent topics addressed in the PsyGist program. The manual will consist of: (1) a section exploring the youth's causal model for their high-risk state; (2) individualization per their causal model; and (3) tutorials that convey the main concepts of genetic malleability. Clinicians will assess individual causal models via discussion with CHR youth about their at- risk state. Individualization of genetic framing will occur using youths' causal models and will fall into 1 of 3 categories (per PsyGist): 'primarily genetic', 'primarily environmental' or 'combined'.

AutoTutor is an intelligent system that simulates talking with a human tutor. Our AutoTutor, called PsyGist, has 3 parts: (1) assessment of the youth's causal model for their high-risk state; (2) an individualized 'pre-tutorial' vignette matched to their causal model; (3) a 'tutorial' presenting the 'genetic malleability' framing. PsyGist will guide participants through its three components.

Outcomes

Primary Outcome Measures

Increased Intent to Engage in Treatment and Healthy Behaviors
Asks participants to rate their likelihood of engaging in treatment and uptake of healthy behaviors if they were told they had a genetic risk for psychosis. (Because this is an exploratory R21 trial, the investigators are also testing and validating new measures for this specific group and purpose).
Behavioral Measure for Intent to Engage in Treatment
New computerized, behavioral task assessing intent to engage in healthy behaviors via time (in seconds) and engagement with (number of clicks) with a social media platform. (Because this is an exploratory R21 trial, the investigators are also testing and validating new measures for this specific group and purpose).

Secondary Outcome Measures

Self-Stigma About Genetic Risk for Psychosis Development
Assess participants self-stigma if they were told they had a genetic risk for psychosis. 7 items, measured on a 4-point scale (strongly disagree, somewhat disagree, somewhat agree, strongly agree). Because this an exploratory R21 trial, the investigators are also testing and validating new measures for this specific group and purpose; however, this is based off a published stereotype awareness and agreement scale previously used among CHR (Yang et al., 2015)
Anticipated Discrimination from Others Due to Genetic Risk for Psychosis Development
Assess participants anticipated discrimination if they were told they had a genetic risk for psychosis. 18 items measured on a 4-point scale (very unlikely, somewhat unlikely, somewhat likely, very likely). Because this is an exploratory R21 trial, the investigators are also testing and validating new measures for this specific group and purpose however, this is based off a published discrimination scale (Wahl, 1999).
Anticipated Rejection from Others Due to Genetic Risk for Psychosis Development
Assess participants anticipated rejection if they were told they had a genetic risk for psychosis. 3 items measured on a 4-point scale (very unconcerned, somewhat unconcerned, somewhat concerned, very concerned). Because this is an exploratory R21 trial, the investigators are also testing and validating new measures for this specific group and purpose; however, these items are based off of a published rejection sensitivity scale (Link, Wells, Phelan, Yang, 2015).
Implicit Association Test
Measures associations to 'Normal/Abnormal' and 'Changeable/Permanent' stereotypes.

Full Information

First Posted
October 31, 2019
Last Updated
January 24, 2023
Sponsor
New York University
Collaborators
New York State Psychiatric Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT04325568
Brief Title
Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis
Official Title
Developing Clinical Translational Tools to Communicate Genetic Risk Among Individuals Who Are at Clinical High Risk for Psychosis
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
November 16, 2020 (Actual)
Primary Completion Date
July 31, 2022 (Actual)
Study Completion Date
July 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
New York University
Collaborators
New York State Psychiatric Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
While great strides are being made in identifying early signs that place people at a 'high risk state' for different illness conditions, at the same time, advances are being made in the identification of genes associated with 'high-risk states'. This study proposes to develop two innovative clinical tools that could greatly facilitate dissemination of a beneficial genetic malleability framing to high-risk youth in order to encourage increased treatment engagement and uptake of healthy behaviors. The impact of genetic information assumes special importance in the 'high-risk state' because achieving the best possible outcome is more likely if individuals actively choose to engage in beneficial treatment and health-promoting behaviors.
Detailed Description
This project seeks to understand how individuals already in a high-risk state will interpret genetic information informing risk of 'conversion' to a full disorder. How individuals interpret this possibility carries important consequences for how they choose to respond, which may range from fatalistic acceptance of the disorder to proactive preventative behavior. With the aim to encourage an active pro-health response, the investigators propose developing two tools for communicating genetic risk and evaluate them regarding their effectiveness in inducing a positive response to the risk of illness. The two tools will consist of: 1) a clinician manual, designed to be used by trained clinicians to communicate risk to CHR youth; 2) a high-impact, computerized tutorial ('AutoTutor') that has been used to convey genetic risk for breast cancer (i.e. BRCA gene). To create these two tools, experts in psychiatric genetics and stigma will work to develop the two tools to convey genetic risk information to youth and young adults identified as in a 'clinical high-risk state' (CHR) for psychosis. The investigators assess primary outcomes of increased intent to engage in treatment and healthy behaviors, and a secondary outcome of reduction in stigma. While specific genes for risk of psychosis are not yet used in diagnosis or treatment, a genetic malleability (GM) framing conforms to the known genetic risk for psychosis, and has a strong likelihood of being used in the not too distant future. Because of the relatively large innovation involved, the investigators seek to establish initial acceptability, safety, and efficacy of each tool. The investigators then use a nonrandomized, within- subject, pre- vs. post design to examine whether providing the genetic malleability framing via each tool (n=27 CHR youth per tool, N=54 total) leads to improved outcomes. For each tool, participants will be conveyed hypothetical information proposing being identified as having a substantially elevated, genetically-malleable risk for developing psychosis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Psychosis

7. Study Design

Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Model Description
This is a pre-post design (N=54) in which the first 27 participants will take part in the clinician manual intervention and the next 27 participants will be assigned to the AutoTutor. Participants will only complete either the clinical manual intervention or the AutoTutor intervention, but not both. These groups will not be compared to one another. Each participant will be assessed on all outcomes before and after the intervention and will only take part in either the clinician manual or Autotutor. Since each participant is only getting one intervention and the clinician manual and AutoTutor are not being compared to each other the most appropriate study design is single group (and cannot be considered factorial, crossover, parallel, or sequential).
Masking
None (Open Label)
Masking Description
Masking will not be used. Again, the 27 participants will be assigned to the clinician manual and the next 27 participants will be assigned to Autotutor. The investigators are doing this in order to prevent contamination.
Allocation
Non-Randomized
Enrollment
25 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Clinician Manual
Arm Type
Other
Arm Description
Participants in the Clinician Manual arm will be introduced to a trained clinician and will complete one 60-minute session covering equivalent topics addressed in the PsyGist program. The manual will consist of: (1) a section exploring the youth's causal model for their high-risk state; (2) individualization per their causal model; and (3) tutorials that convey the main concepts of genetic malleability. Clinicians will assess individual causal models via discussion with CHR youth about their at- risk state. Individualization of genetic framing will occur using youths' causal models and will fall into 1 of 3 categories (per PsyGist): 'primarily genetic', 'primarily environmental' or 'combined'.
Arm Title
AutoTutor (PsyGist)
Arm Type
Other
Arm Description
AutoTutor is an intelligent system that simulates talking with a human tutor. Our AutoTutor, called PsyGist, has 3 parts: (1) assessment of the youth's causal model for their high-risk state; (2) an individualized 'pre-tutorial' vignette matched to their causal model; (3) a 'tutorial' presenting the 'genetic malleability' framing. PsyGist will guide participants through its three components.
Intervention Type
Behavioral
Intervention Name(s)
PsyGist and Clinician Manual
Intervention Description
This is a pre-post test design aimed at conveying future genetic risk information to those at clinical high risk for psychosis. Participants will be assigned to either complete the Clinician Manual intervention (n= 27 participants) or PsyGist intervention (n=27 participants).
Primary Outcome Measure Information:
Title
Increased Intent to Engage in Treatment and Healthy Behaviors
Description
Asks participants to rate their likelihood of engaging in treatment and uptake of healthy behaviors if they were told they had a genetic risk for psychosis. (Because this is an exploratory R21 trial, the investigators are also testing and validating new measures for this specific group and purpose).
Time Frame
15 minutes
Title
Behavioral Measure for Intent to Engage in Treatment
Description
New computerized, behavioral task assessing intent to engage in healthy behaviors via time (in seconds) and engagement with (number of clicks) with a social media platform. (Because this is an exploratory R21 trial, the investigators are also testing and validating new measures for this specific group and purpose).
Time Frame
15 minutes
Secondary Outcome Measure Information:
Title
Self-Stigma About Genetic Risk for Psychosis Development
Description
Assess participants self-stigma if they were told they had a genetic risk for psychosis. 7 items, measured on a 4-point scale (strongly disagree, somewhat disagree, somewhat agree, strongly agree). Because this an exploratory R21 trial, the investigators are also testing and validating new measures for this specific group and purpose; however, this is based off a published stereotype awareness and agreement scale previously used among CHR (Yang et al., 2015)
Time Frame
5 minutes
Title
Anticipated Discrimination from Others Due to Genetic Risk for Psychosis Development
Description
Assess participants anticipated discrimination if they were told they had a genetic risk for psychosis. 18 items measured on a 4-point scale (very unlikely, somewhat unlikely, somewhat likely, very likely). Because this is an exploratory R21 trial, the investigators are also testing and validating new measures for this specific group and purpose however, this is based off a published discrimination scale (Wahl, 1999).
Time Frame
5 minutes
Title
Anticipated Rejection from Others Due to Genetic Risk for Psychosis Development
Description
Assess participants anticipated rejection if they were told they had a genetic risk for psychosis. 3 items measured on a 4-point scale (very unconcerned, somewhat unconcerned, somewhat concerned, very concerned). Because this is an exploratory R21 trial, the investigators are also testing and validating new measures for this specific group and purpose; however, these items are based off of a published rejection sensitivity scale (Link, Wells, Phelan, Yang, 2015).
Time Frame
5 minutes
Title
Implicit Association Test
Description
Measures associations to 'Normal/Abnormal' and 'Changeable/Permanent' stereotypes.
Time Frame
15 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or females between the ages of 16- 30 Current or previous COPE participant Identified as at clinical high risk for psychosis as defined as having at least one of the following: a)attenuated positive symptoms b)brief intermittent positive symptoms Exclusion Criteria: Meeting CHR via only the Genetic risk and deterioration (GRD) syndrome. If the participant meets the GRD syndrome only, the investigators exclude the rare Genetic risk + deterioration (GRD) syndrome (comprising <1% of CHR cases) because GRD requires having a 1st degree relative with any psychotic disorder, which may be linked with stronger reactions to genetic framings. IQ < 80 Inability to adopt hypothetical situation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lawrence Yang, PhD
Organizational Affiliation
New York University
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York State Psychiatric Institute
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There is not a plan to make IPD available.

Learn more about this trial

Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis

We'll reach out to this number within 24 hrs